Increased vascular angiotensin II binding capacity and ET-1 release in young cardiomyopathic hamsters

Vascular Pharmacology
Maria J CrespoNelson Escobales

Abstract

Heart failure (HF) is a multifactorial and progressive disease that has been associated with multiple systemic and vascular alterations. Previous reports from our laboratory showed that in 2-month-old Bio-To2 Syrian cardiomyopathic hamsters (SCH) that have not yet developed the clinical manifestations of HF, the vascular contractility induced by 0.1 microM angiotensin II was approximately 35% greater than in control animals. This finding was observed concomitantly with an increased aortic ACE activity. To further evaluate the mechanisms underlying angiotensin II-enhanced vascular contraction, concentration-response curves for angiotensin II (0.01 nM-10 microM) were constructed before and after the addition of prazosin (alpha-1 blocker), NS-398 (selective COX-2 blocker) and BQ-123 (ET-1A-receptor antagonist) in aortic rings from 2-month-old SCH. The binding capacity and affinity of the AT-1 receptors were also evaluated in aortic homogenates using 125I-angiotensin II. Age-matched golden hamsters were used as controls (CT). Our results indicate that incubation with either 10 microM prazosin or 10 microM NS-398 did not modify EC50 or Emax values for angiotensin II indicating that norepinephrine and prostaglandins are not involved ...Continue Reading

References

Jan 1, 1992·Journal of Cardiovascular Pharmacology·P R Saxena
Jan 1, 1991·Journal of Cardiovascular Pharmacology·W G HaynesD J Webb
Sep 1, 1990·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M S Simonson, M J Dunn
Oct 2, 1990·The American Journal of Cardiology·G S Francis
Jan 16, 1995·European Journal of Pharmacology·P A CahillJ V Sitzmann
Aug 18, 1993·Biochimica Et Biophysica Acta·B H ChuaB B Siu
May 1, 1994·Current Opinion in Cardiology·G S Francis, C Chu
Jul 9, 1997·European Journal of Pharmacology·J H Burrell, E R Lumbers
Apr 21, 1998·Journal of Cardiac Failure·M J CrespoN Escobales
Jul 30, 1999·Biochemical and Biophysical Research Communications·M AkishitaM Horiuchi
Sep 18, 1999·Cell·K R Chien
Oct 6, 1999·Prostaglandins, Leukotrienes, and Essential Fatty Acids·G K Oriji
Nov 7, 2002·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jongun LeeSoo Wan Kim
Dec 5, 2003·Postgraduate Medical Journal·D B McKenzie, A J Cowley
Jul 31, 2004·Acta Physiologica Scandinavica·R C HarrisH-F Cheng
Sep 24, 2004·Canadian Journal of Physiology and Pharmacology·Valdeci da CunhaJosé Geraldo Mill
Dec 16, 2004·American Journal of Physiology. Heart and Circulatory Physiology·YingJie ChenRobert J Bache
Apr 19, 2005·Journal of Hypertension·Markus P SchlaichMurray D Esler

❮ Previous
Next ❯

Citations

Dec 15, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·María J CrespoNelson Escobales
Jul 3, 2008·Journal of Cardiovascular Pharmacology and Therapeutics·Maria J CrespoNelson Escobales
Mar 1, 2012·Journal of Cardiovascular Pharmacology·Maria J CrespoNelson Escobales

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.